Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -80%. A quarter ago, it was expected that this company would post a loss of $0.05 per share when it actually produced a loss of $0.08, delivering a surprise of -60%.Over the last four quarters, the company has surpassed c ...

Revenue Performance - Revenue for Q4 2024 was $6.3 million, a 39% increase from $4.6 million in Q4 2023[5] - Full year 2024 revenue totaled $26.9 million, slightly up from $26.8 million in 2023[5] - System revenue for Q4 2024 was $1.4 million, while recurring revenue was $4.9 million, compared to $0.1 million and $4.5 million in Q4 2023, respectively[5] - Stereotaxis expects double-digit revenue growth for the full year 2025, with recurring revenue projected to scale from $5 million in Q1 to $7 million in Q4[9] Profitability and Loss - Gross margin for Q4 2024 was approximately 51%, with full year gross margins at 54%[6] - Operating loss for Q4 2024 was ($7.6) million, compared to ($5.3) million in Q4 2023[7] - Adjusted operating loss for the full year 2024 was ($12.8) million, compared to ($11.3) million in 2023[7] Financial Position - Cash and cash equivalents at year-end 2024 were $12.4 million, with no debt[8] - System backlog at the start of 2025 is $15.2 million[5] Future Outlook - Anticipated regulatory milestones and initial commercial launches in 2025 are expected to support substantial growth in 2026[9]

Core Insights - Stereotaxis has announced the FDA regulatory submission for the EMAGIN™ 5F, the first robotically navigated catheter aimed at expanding Robotic Magnetic Navigation into the endovascular field [1][2] - The EMAGIN brand will include a range of robotic catheters and wires, with the 5F catheter designed for navigating complex vascular structures [2] - The company anticipates launching the EMAGIN 5F in the second half of 2025, following expected regulatory approvals [3][4] Company Overview - Stereotaxis is a leader in surgical robotics for minimally invasive endovascular interventions, with a mission to develop robotic systems that enhance patient care and operational efficiency [5] - The technology has been utilized in over 150,000 procedures globally, indicating a strong market presence and acceptance [5] Industry Impact - Robotic Magnetic Navigation is positioned to address significant clinical challenges in neurointerventional and interventional cardiology, enhancing safety and precision in complex procedures [3][4] - Experts in the field express optimism about the potential of the EMAGIN catheter to improve outcomes in various challenging medical procedures [3]

Core Insights - Stereotaxis has announced the FDA regulatory submission for the MAGiC Sweep™ catheter, marking a significant advancement in surgical robotics for minimally invasive endovascular interventions [1][3] - The MAGiC Sweep is the first high-density electrophysiology (EP) mapping catheter designed for robotic navigation, which is expected to enhance cardiac ablation procedures through improved mapping capabilities [2][3] Company Developments - The MAGiC Sweep catheter allows for rapid and detailed electroanatomical mapping from 20 electrodes, improving safety and accuracy in mapping difficult areas of the heart [2][3] - Stereotaxis plans to submit the MAGiC Sweep for European CE Mark clearance and anticipates a broad commercial launch in the second half of the year following expected regulatory approvals [3][4] - The company has also introduced the EMAGIN 5F vascular guidance catheter, indicating a strategic expansion of its product portfolio [4] Industry Impact - The introduction of the MAGiC Sweep catheter is seen as a major milestone in the EP field, potentially transforming the approach to arrhythmia treatment by enabling high-resolution mapping [3] - Stereotaxis aims to solidify its position as a leader in robotic technology with a diverse range of proprietary catheters, reflecting its commitment to innovation in surgical robotics [4]

Core Insights - Stereotaxis reported a 39% year-over-year revenue growth in Q4 2024, reaching $6.3 million, driven by increased robotic system revenue and successful integration of APT [4][6] - The company achieved several regulatory milestones, including European approval for the MAGiC catheter and the first sale of the GenesisX robot, which are expected to enhance commercial growth [3][4] - Stereotaxis anticipates double-digit revenue growth for the full year 2025, with recurring revenue projected to scale from $5 million in Q1 to $7 million in Q4 [8][9] Financial Performance - Q4 2024 revenue was $6.3 million, up from $4.6 million in Q4 2023, with system revenue at $1.4 million and recurring revenue at $4.9 million [4][6] - Full year 2024 revenue totaled $26.9 million, slightly up from $26.8 million in 2023, with a system backlog of $15.2 million at the start of 2025 [4][6] - Gross margins for Q4 and full year 2024 were approximately 51% and 54%, respectively, with recurring revenue gross margins at 70% and system revenue at 20% [5][6] Cash Flow and Balance Sheet - Stereotaxis generated positive cash flow of $1.3 million in Q4 2024, ending the year with over $12 million in cash and no debt [6][7] - The company reported a negative free cash flow of $8.5 million for the full year 2024, an improvement from $9.5 million in 2023 [6][10] - Total assets increased to $46.7 million in 2024 from $41.9 million in 2023, while total liabilities rose to $35.3 million from $20.0 million [17][19] Strategic Outlook - The company is focused on expanding its catheter portfolio and expects modest contributions from new innovations initially, with potential for breakout growth in the future [3][9] - Stereotaxis aims to reduce cash use in 2025 compared to the previous year, supported by growing recurring revenue and stable operating expenses [10]

Core Insights - Stereotaxis is participating in TD Cowen's 45th Annual Healthcare Conference, with CEO David Fischel presenting on March 3, 2025 [1][2] - The company aims to share its progress and strategy during the conference [2] Company Overview - Stereotaxis is a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention [3] - The company's mission focuses on the discovery, development, and delivery of robotic systems, instruments, and information solutions for interventional laboratories [3] - Stereotaxis technology has been utilized to treat over 150,000 patients globally, including in the United States, Europe, and Asia [3]

Group 1 - The company Stereotaxis (NYSE: STXS) was initially expected to receive approval for its MAGiC technology in Europe by late 2022 and in the United States two years later, indicating a miscalculation in the timeline for regulatory approval [1] - Stereotaxis represents the largest investment position for the analyst, highlighting significant confidence in the company's potential [2]

Company Developments - Stereotaxis, Inc. has received its first order for the GenesisX robotic system from a European hospital, marking a significant step in expanding the adoption of robotics in endovascular interventions [1][3] - GenesisX, which has received CE Mark approval in Europe and is pending FDA clearance, is designed to simplify installation and operational requirements, making it more accessible for hospitals [3][5] - The system is smaller and lighter than previous models, requiring no structural anchoring and operating on standard power outlets, which enhances its usability in operating rooms [6] Financial Performance - Stereotaxis has a market capitalization of $205.1 million, with a Zacks Consensus Estimate indicating a 37.2% year-over-year increase in fiscal 2025 earnings, alongside a 67.5% revenue improvement [4] Industry Prospects - The global surgical robots market is projected to grow from $9.6 billion in 2023 to $23.7 billion by 2029, reflecting a compound annual growth rate of 16.6% [8] - The demand for minimally invasive surgery is increasing due to its benefits, such as improved precision and shorter hospital stays, which is driving market expansion [9] Recent Innovations - In January, Stereotaxis received CE Mark approval for the MAGiC ablation catheter, which is designed for cardiac ablation procedures, further establishing its presence in the robotics field [10]

Core Viewpoint - Stereotaxis will announce its financial results for the fourth quarter and full year of 2024 on March 3, 2025, before the U.S. financial markets open, followed by a conference call to discuss the results and corporate developments [1]. Group 1: Financial Results Announcement - The financial results for the fourth quarter and full year of 2024 will be released on March 3, 2025 [1]. - A conference call and webcast will take place at 8:30 a.m. ET on the same day to discuss the results [1][2]. Group 2: Company Overview - Stereotaxis is a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention [3]. - The company's mission focuses on the discovery, development, and delivery of robotic systems, instruments, and information solutions for interventional laboratories [3]. - Stereotaxis technology has been utilized to treat over 150,000 patients globally, enhancing patient care with robotic precision and safety [3].

Core Insights - Stereotaxis has received its first order for the GenesisX robotic system, marking a significant milestone towards its commercial launch [1][2] - The GenesisX system enhances the accessibility of Robotic Magnetic Navigation in endovascular surgery, featuring a compact design and requiring no structural anchoring [2][3] - The company aims to obtain regulatory approvals for GenesisX and compatible catheters in both Europe and the US during 2025 [3] Company Overview - Stereotaxis is a leader in surgical robotics for minimally invasive endovascular interventions, focusing on the development of robotic systems and solutions to improve patient care [4] - The technology has been utilized to treat over 150,000 patients globally, demonstrating its impact in the healthcare sector [4]